31 results on '"Juan C. Roa"'
Search Results
2. Female offspring gestated in hypothyroxinemia and infected with human Metapneumovirus (hMPV) suffer a more severe infection and have a higher number of activated CD8+ T lymphocytes
- Author
-
Samanta C. Funes, Mariana Ríos, Ayleen Fernández-Fierro, Daniela Rivera-Pérez, Jorge A. Soto, José R. Valbuena, María J. Altamirano-Lagos, Felipe Gómez-Santander, Evelyn L. Jara, Pablo Zoroquiain, Juan C. Roa, Alexis M. Kalergis, and Claudia A. Riedel
- Subjects
thyroid hormones ,gestational hypothyroxinemia ,human metapneumovirus (hMPV) ,viral infection ,metapneumo virus ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Maternal thyroid hormones (THs) are essential for the appropriate development of the fetus and especially for the brain. Recently, some studies have shown that THs deficiency can also alter the immune system development of the progeny and their ability to mount an appropriate response against infectious agents. In this study, we evaluated whether adult mice gestated under hypothyroxinemia (Hpx) showed an altered immune response against infection with human metapneumovirus (hMPV). We observed that female mice gestated under Hpx showed higher clinical scores after seven days of hMPV infection. Besides, males gestated under Hpx have higher lung viral loads at day seven post-infection. Furthermore, the female offspring gestated in Hpx have already reduced the viral load at day seven and accordingly showed an increased proportion of activated (CD71+ and FasL+) CD8+ T cells in the lungs, which correlated with a trend for a higher histopathological clinical score. These results support that T4 deficiency during gestation might condition the offspring differently in males and females, enhancing their ability to respond to hMPV.
- Published
- 2022
- Full Text
- View/download PDF
3. Exploring the Genetic Diversity of Epstein–Barr Virus among Patients with Gastric Cancer in Southern Chile
- Author
-
María Elena Reyes, Louise Zanella, Ismael Riquelme, Kurt Buchegger, Bárbara Mora-Lagos, Pablo Guzmán, Patricia García, Juan C. Roa, Carmen Gloria Ili, and Priscilla Brebi
- Subjects
gastric cancer ,Epstein–Barr virus (EBV) ,EBNA3A ,phylogeny ,Chile ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The Epstein–Barr virus (EBV) has been associated with gastric cancer (GC), one of the deadliest malignancies in Chile and the world. Little is known about Chilean EBV strains. This study aims to investigate the frequency and genetic diversity of EBV in GC in patients in southern Chile. To evaluate the prevalence of EBV in GC patients from the Chilean population, we studied 54 GC samples using the gold standard detection method of EBV-encoded small RNA (EBER). The EBV-positive samples were subjected to amplification and sequencing of the Epstein–Barr virus nuclear protein 3A (EBNA3A) gene to evaluate the genetic diversity of EBV strains circulating in southern Chile. In total, 22.2% of the GC samples were EBV-positive and significantly associated with diffuse-type histology (p = 0.003). Phylogenetic analyses identified EBV-1 and EBV-2 in the GC samples, showing genetic diversity among Chilean isolates. This work provides important information for an epidemiological follow-up of the different EBV subtypes that may cause GC in southern Chile.
- Published
- 2023
- Full Text
- View/download PDF
4. A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance
- Author
-
Luis Vergara-Gómez, Carolina Bizama, Jun Zhong, Kurt Buchegger, Felipe Suárez, Lorena Rosa, Carmen Ili, Helga Weber, Javiera Obreque, Karena Espinoza, Gabriela Repetto, Juan C. Roa, Pamela Leal, and Patricia García
- Subjects
gallbladder cancer ,acquired drug resistance ,gemcitabine ,epithelial-to-mesenchymal transition ,gene expression profiling ,SILAC-based phosphoproteomics ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Treatment options for advanced gallbladder cancer (GBC) are scarce and usually rely on cytotoxic chemotherapy, but the effectiveness of any regimen is limited and recurrence rates are high. Here, we investigated the molecular mechanisms of acquired resistance in GBC through the development and characterization of two gemcitabine-resistant GBC cell sublines (NOZ GemR and TGBC1 GemR). Morphological changes, cross-resistance, and migratory/invasive capabilities were evaluated. Then, microarray-based transcriptome profiling and quantitative SILAC-based phosphotyrosine proteomic analyses were performed to identify biological processes and signaling pathways dysregulated in gemcitabine-resistant GBC cells. The transcriptome profiling of parental and gemcitabine-resistant cells revealed the dysregulation of protein-coding genes that promote the enrichment of biological processes such as epithelial-to-mesenchymal transition and drug metabolism. On the other hand, the phosphoproteomics analysis of NOZ GemR identified aberrantly dysregulated signaling pathways in resistant cells as well as active kinases, such as ABL1, PDGFRA, and LYN, which could be novel therapeutic targets in GBC. Accordingly, NOZ GemR showed increased sensitivity toward the multikinase inhibitor dasatinib compared to parental cells. Our study describes transcriptome changes and altered signaling pathways occurring in gemcitabine-resistant GBC cells, which greatly expands our understanding of the underlying mechanisms of acquired drug resistance in GBC.
- Published
- 2023
- Full Text
- View/download PDF
5. Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia
- Author
-
Lorena Rosa, Lorena Lobos‐González, Natalia Muñoz‐Durango, Patricia García, Carolina Bizama, Natalia Gómez, Ximena González, Ignacio A. Wichmann, Nicolás Saavedra, Francisca Guevara, Jaime Villegas, Marco Arrese, Catterina Ferreccio, Alexis M. Kalergis, Juan Francisco Miquel, Jaime A. Espinoza, and Juan C. Roa
- Subjects
chronic inflammation ,dysplasia ,gallbladder cancer ,gallstones ,lithogenic diet ,metaplasia ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Gallbladder stones (cholecystolithiasis) are the main risk factor for gallbladder cancer (GBC), a lethal biliary malignancy with poor survival rates worldwide. Gallbladder stones are thought to damage the gallbladder epithelium and trigger chronic inflammation. Preneoplastic lesions that arise in such an inflammatory microenvironment can eventually develop into invasive carcinoma, through mechanisms that are not fully understood. Here, we developed a novel gallbladder preneoplasia mouse model through the administration of two lithogenic diets (a low‐ or a high‐cholesterol diet) in wild‐type C57BL/6 mice over a period of 9 months. Additionally, we evaluated the chemopreventive potentials of the anti‐inflammatory drug aspirin and the cholesterol absorption inhibitor ezetimibe. Both lithogenic diets induced early formation of gallbladder stones, together with extensive inflammatory changes and widespread induction of metaplasia, an epithelial adaptation to tissue injury. Dysplastic lesions were presented only in mice fed with high‐cholesterol diet (62.5%) in late stages (9th month), and no invasive carcinoma was observed at any stage. The cholesterol absorption inhibitor ezetimibe inhibited gallbladder stone formation and completely prevented the onset of metaplasia and dysplasia in both lithogenic diets, whereas aspirin partially reduced metaplasia development only in the low‐cholesterol diet setting. This model recapitulates several of the structural and inflammatory findings observed in human cholecystolithiasic gallbladders, making it relevant for the study of gallbladder carcinogenesis. In addition, our results suggest that the use of cholesterol absorption inhibitors and anti‐inflammatory drugs can be evaluated as chemopreventive strategies to reduce the burden of GBC among high‐risk populations.
- Published
- 2020
- Full Text
- View/download PDF
6. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
- Author
-
María F. Mercogliano, Gloria Inurrigarro, Mara De Martino, Leandro Venturutti, Martín A. Rivas, Rosalía Cordo-Russo, Cecilia J. Proietti, Elmer A. Fernández, Isabel Frahm, Sabrina Barchuk, Daniel H. Allemand, Silvina Figurelli, Ernesto Gil Deza, Sandra Ares, Felipe G. Gercovich, Eduardo Cortese, Matías Amasino, Pablo Guzmán, Juan C. Roa, Patricia V. Elizalde, and Roxana Schillaci
- Subjects
Invasive micropapillary carcinoma of the breast (IMPC) ,HER2 ,Mucin 4 (MUC4) ,Trastuzumab ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Invasive micropapillary carcinoma of the breast (IMPC) is a histological tumor variant that occurs with low frequency characterized by an inside-out formation of tumor clusters with a pseudopapillary arrangement. IMPC is an aggressive tumor with poor clinical outcome. In addition, this histological subtype usually expresses human epidermal growth factor receptor 2 (HER2) which also correlates with a more aggressive tumor. In this work we studied the clinical significance of IMPC in HER2-positive breast cancer patients treated with adjuvant trastuzumab. We also analyzed mucin 4 (MUC4) expression as a novel biomarker to identify IMPC. Methods We retrospectively studied 86 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy in the adjuvant setting. We explored the association of the IMPC component with clinicopathological parameters at diagnosis and its prognostic value. We compared MUC4 expression in IMPC with respect to other histological breast cancer subtypes by immunohistochemistry. Results IMPC, either as a pure entity or associated with invasive ductal carcinoma (IDC), was present in 18.6% of HER2-positive cases. It was positively correlated with estrogen receptor expression and tumor size and inversely correlated with patient’s age. Disease-free survival was significantly lower in patients with IMPC (hazard ratio = 2.6; 95%, confidence interval 1.1–6.1, P = 0.0340). MUC4, a glycoprotein associated with metastasis, was strongly expressed in all IMPC cases tested. IMPC appeared as the histological breast cancer subtype with the highest MUC4 expression compared to IDC, lobular and mucinous carcinoma. Conclusion In HER2-positive breast cancer, the presence of IMPC should be carefully examined. As it is often not informed, because it is relatively difficult to identify or altogether overlooked, we propose MUC4 expression as a useful biomarker to highlight IMPC presence. Patients with MUC4-positive tumors with IMPC component should be more frequently monitored and/or receive additional therapies.
- Published
- 2017
- Full Text
- View/download PDF
7. MicroRNA-335-5p is a potential suppressor of metastasis and invasion in gastric cancer
- Author
-
Alejandra Sandoval-Bórquez, Iva Polakovicova, Nicolás Carrasco-Véliz, Lorena Lobos-González, Ismael Riquelme, Gonzalo Carrasco-Avino, Carolina Bizama, Enrique Norero, Gareth I. Owen, Juan C. Roa, and Alejandro H. Corvalán
- Subjects
miR-335 ,Gastric cancer ,Metastasis ,PLAUR ,CDH11 ,Methylation ,Medicine ,Genetics ,QH426-470 - Abstract
Abstract Background Multiple aberrant microRNA expression has been reported in gastric cancer. Among them, microRNA-335-5p (miR-335), a microRNA regulated by DNA methylation, has been reported to possess both tumor suppressor and tumor promoter activities. Results Herein, we show that miR-335 levels are reduced in gastric cancer and significantly associate with lymph node metastasis, depth of tumor invasion, and ultimately poor patient survival in a cohort of Amerindian/Hispanic patients. In two gastric cancer cell lines AGS and, Hs 746T the exogenous miR-335 decreases migration, invasion, viability, and anchorage-independent cell growth capacities. Performing a PCR array on cells transfected with miR-335, 19 (30.6%) out of 62 genes involved in metastasis and tumor invasion showed decreased transcription levels. Network enrichment analysis narrowed these genes to nine (PLAUR, CDH11, COL4A2, CTGF, CTSK, MMP7, PDGFA, TIMP1, and TIMP2). Elevated levels of PLAUR, a validated target gene, and CDH11 were confirmed in tumors with low expression of miR-335. The 3′UTR of CDH11 was identified to be directly targeted by miR-335. Downregulation of miR-335 was also demonstrated in plasma samples from gastric cancer patients and inversely correlated with DNA methylation of promoter region (Z = 1.96, p = 0.029). DNA methylation, evaluated by methylation-specific PCR assay, was found in plasma from 23 (56.1%) out of 41 gastric cancer patients but in only 9 (30%) out of 30 healthy donors (p = 0.029, Pearson’s correlation). Taken in consideration, our results of the association with depth of invasion, lymph node metastasis, and poor prognosis together with functional assays on cell migration, invasion, and tumorigenicity are in accordance with the downregulation of miR-335 in gastric cancer. Conclusions Comprehensive evaluation of metastasis and invasion pathway identified a subset of associated genes and confirmed PLAUR and CDH11, both targets of miR-335, to be overexpressed in gastric cancer tissues. DNA methylation of miR-335 may be a promissory strategy for non-invasive approach to gastric cancer.
- Published
- 2017
- Full Text
- View/download PDF
8. Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile
- Author
-
Priscilla Brebi, Carmen Gloria Ili, Alejandra Andana, Doris Menzel, Jaime Lopez, Pablo Guzman, Angelica Melo, Kurt Buchegger, and Juan C. Roa
- Subjects
Human papillomavirus ,Cervical intraepithelial neoplasia ,Cervical cancer ,Polymerase chain reaction ,Reverse line blotting assay ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Human papillomavirus (HPV) is the etiological factor for cervical cancer and its precursor lesions. The characterization of HPV genotypes in preneoplastic lesions and cervical cancer could establishes the effectiveness of vaccination plan in Chilean population. The aim of this study was to determine HPV frequency in a group of women including in a cervical screening program in the public health care system in Chile. Methods We analyzed 985 cervical smears samples from women with different histological diagnosis, attending to public health care in Temuco-Chile between 2004 and 2012, to detect HPV genotypes, through PCR followed by reverse line blotting assay. Results HPV was found present in 80.8% (n = 796) of samples. Only a 5.6% of 985 samples were infected with a low-risk HPV, considering multiple infections. 10.5% (n = 8/76) of normal cervical epithelia, 83.5% (n = 208/249) and 87.6% (n = 557/636) of low and high grade squamous intraepithelial lesions, respectively, and 95.8% (n = 23/24) of squamous cervical carcinomas tested positive for HPV. HPV 16 was the most frequent genotype found (Overall 44.9%, n = 442/985; SCC: 62.5%, n = 15/24). A high variability of HPV types was also found in preneoplastic lesions, whereas there was a selection of genotypes in neoplasia. Also, there was a higher risk of infection with HPV 16 in women ≤26 years and 34–41 years old (p
- Published
- 2017
- Full Text
- View/download PDF
9. Salmonella enterica serovar Typhi and gallbladder cancer: a case–control study and meta‐analysis
- Author
-
Jill Koshiol, Aniela Wozniak, Paz Cook, Christina Adaniel, Johanna Acevedo, Lorena Azócar, Ann W. Hsing, Juan C. Roa, Marcela F. Pasetti, Juan F. Miquel, Myron M. Levine, Catterina Ferreccio, and the Gallbladder Cancer Chile Working Group
- Subjects
Chile ,epidemiology ,gallbladder cancer ,meta‐analysis ,Salmonella enterica serovar Typhi ,Vi antibodies ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract In Chile, where gallbladder cancer (GBC) rates are high and typhoid fever was endemic until the 1990s, we evaluated the association between Salmonella enterica serovar Typhi (S. Typhi) antibodies and GBC. We tested 39 GBC cases, 40 gallstone controls, and 39 population‐based controls for S. Typhi Vi antibodies and performed culture and quantitative polymerase chain reaction for the subset with bile, gallstone, tissue, and stool samples available. We calculated gender and education‐adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association with GBC. We also conducted a meta‐analysis of >1000 GBC cases by combining our results with previous studies. GBC cases were more likely to have high Vi antibody titer levels than combined controls (OR: 4.0, 95% CI: 0.9–18.3), although S. Typhi was not recovered from bile, gallstone, tissue, or stool samples. In our meta‐analysis, the summary relative risk was 4.6 (95% CI: 3.1–6.8, Pheterogeneity=0.6) for anti‐Vi and 5.0 (95% CI: 2.7–9.3, Pheterogeneity = 0.2) for bile or stool culture. Our results are consistent with the meta‐analysis. Despite differences in study methods (e.g., S. Typhi detection assay), most studies found a positive association between S. Typhi and GBC. However, the mechanism underlying this association requires further investigation
- Published
- 2016
- Full Text
- View/download PDF
10. Exploring the Genetic Diversity of Epstein–Barr Virus among Patients with Gastric Cancer in Southern Chile
- Author
-
Brebi, María Elena Reyes, Louise Zanella, Ismael Riquelme, Kurt Buchegger, Bárbara Mora-Lagos, Pablo Guzmán, Patricia García, Juan C. Roa, Carmen Gloria Ili, and Priscilla
- Subjects
gastric cancer ,Epstein–Barr virus (EBV) ,EBNA3A ,phylogeny ,Chile - Abstract
The Epstein–Barr virus (EBV) has been associated with gastric cancer (GC), one of the deadliest malignancies in Chile and the world. Little is known about Chilean EBV strains. This study aims to investigate the frequency and genetic diversity of EBV in GC in patients in southern Chile. To evaluate the prevalence of EBV in GC patients from the Chilean population, we studied 54 GC samples using the gold standard detection method of EBV-encoded small RNA (EBER). The EBV-positive samples were subjected to amplification and sequencing of the Epstein–Barr virus nuclear protein 3A (EBNA3A) gene to evaluate the genetic diversity of EBV strains circulating in southern Chile. In total, 22.2% of the GC samples were EBV-positive and significantly associated with diffuse-type histology (p = 0.003). Phylogenetic analyses identified EBV-1 and EBV-2 in the GC samples, showing genetic diversity among Chilean isolates. This work provides important information for an epidemiological follow-up of the different EBV subtypes that may cause GC in southern Chile.
- Published
- 2023
- Full Text
- View/download PDF
11. Supplementary Figure Legends from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- Author
-
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, and María F. Mercogliano
- Abstract
Supplementary Figure Legends
- Published
- 2023
12. Data from Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer
- Author
-
Anirban Maitra, Gregory J. Riggins, Alfonso Diaz, Fernando Pimentel, Luis Ibañez, Ivan Roa, Michael Mullendore, Seung-Mo Hong, Georg Feldmann, Robert Beaty, Jennifer Edwards, Francisco Murillo, Pedram Argani, Juan C. Roa, Alejandro Corvalan, and Hector Alvarez
- Abstract
Background: Gallbladder cancer (GBC) is an uncommon neoplasm in the United States, but one with high mortality rates. This malignancy remains largely understudied at the molecular level such that few targeted therapies or predictive biomarkers exist.Experimental Design: We built the first series of serial analysis of gene expression (SAGE) libraries from GBC and nonneoplastic gallbladder mucosa, composed of 21-bp long-SAGE tags. SAGE libraries were generated from three stage-matched GBC patients (representing Hispanic/Latino, Native American, and Caucasian ethnicities, respectively) and one histologically alithiasic gallbladder. Real-time quantitative PCR was done on microdissected epithelium from five matched GBC and corresponding nonneoplastic gallbladder mucosa. Immunohistochemical analysis was done on a panel of 182 archival GBC in high-throughput tissue microarray format.Results: SAGE tags corresponding to connective tissue growth factor (CTGF) transcripts were identified as differentially overexpressed in all pairwise comparisons of GBC (P < 0.001). Real-time quantitative PCR confirmed significant overexpression of CTGF transcripts in microdissected primary GBC (P < 0.05), but not in metastatic GBC, compared with nonneoplastic gallbladder epithelium. By immunohistochemistry, 66 of 182 (36%) GBC had high CTGF antigen labeling, which was significantly associated with better survival on univariate analysis (P = 0.0069, log-rank test).Conclusions: An unbiased analysis of the GBC transcriptome by SAGE has identified CTGF expression as a predictive biomarker of favorable prognosis in this malignancy. The SAGE libraries from GBC and nonneoplastic gallbladder mucosa are publicly available at the Cancer Genome Anatomy Project web site and should facilitate much needed research into this lethal neoplasm.
- Published
- 2023
13. Supplementary Figure 1 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- Author
-
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, and María F. Mercogliano
- Abstract
Supplementary Figure S1. Aggressive features of tumors overexpressing TNFα. A-C, H&E staining of BT-474 T2 tumors showing A, muscle and B, dermis infiltration (depicted by arrows). C, peritumor leukocyte infiltration (arrow). D, histopathological analysis of BT-474 T1 tumors. BT-474 T1 tumors were established and treated as described in Figure 2. First and second lines are H&E stainings and third line depicts HER2 staining by IHC. Arrows point out mitotic figures.
- Published
- 2023
14. Supplementary Figure 2 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- Author
-
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, and María F. Mercogliano
- Abstract
Supplementary Figure S2. Determination and scoring of MUC4 and TNFα expression in breast cancer biopsies by IHC. A, tissue microarrays were used to establish a score of MUC4 by IHC analysis as described by Workman et al (17). Score 0 represents no stain to less than 30% of cells stained faintly, 1+ greater than 30% of cells stained with light to moderate intensity, 2+ greater than 50% of cells stained moderately, 3+ intense staining of majority of the epithelial population. The yellow arrow in the inset of MUC4 (score 0) shows positive staining in endothelial cells, used as an internal control. B, TNFα score was equivalent to that described for MUC4. For both proteins scores of 2+ and 3+ were considered as positive expression.
- Published
- 2023
15. Revised Supplementary Tables from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- Author
-
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, and María F. Mercogliano
- Abstract
Supplementary Table S1. Patient baseline characteristics. Supplementary Table S2. Growth rate of TNFα-producing and control BT-474 tumors treated with trastuzumab
- Published
- 2023
16. Data from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- Author
-
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, and María F. Mercogliano
- Abstract
Purpose: Although trastuzumab administration improved the outcome of HER2-positive breast cancer patients, resistance events hamper its clinical benefits. We demonstrated that TNFα stimulation in vitro induces trastuzumab resistance in HER2-positive breast cancer cell lines. Here, we explored the mechanism of TNFα-induced trastuzumab resistance and the therapeutic strategies to overcome it.Experimental Design: Trastuzumab-sensitive breast cancer cells, genetically engineered to stably overexpress TNFα, and de novo trastuzumab-resistant tumors, were used to evaluate trastuzumab response and TNFα-blocking antibodies effectiveness respectively. Immunohistochemistry and antibody-dependent cell cytotoxicity (ADCC), together with siRNA strategy, were used to explore TNFα influence on the expression and function of its downstream target, mucin 4 (MUC4). The clinical relevance of MUC4 expression was studied in a cohort of 78 HER2-positive breast cancer patients treated with adjuvant trastuzumab.Results: TNFα overexpression turned trastuzumab-sensitive cells and tumors into resistant ones. Histopathologic findings revealed mucin foci in TNFα-producing tumors. TNFα induced upregulation of MUC4 that reduced trastuzumab binding to its epitope and impaired ADCC. Silencing MUC4 enhanced trastuzumab binding, increased ADCC, and overcame trastuzumab and trastuzumab-emtansine antiproliferative effects in TNFα-overexpressing cells. Accordingly, administration of TNFα-blocking antibodies downregulated MUC4 and sensitized de novo trastuzumab-resistant breast cancer cells and tumors to trastuzumab. In HER2-positive breast cancer samples, MUC4 expression was found to be an independent predictor of poor disease-free survival (P = 0.008).Conclusions: We identified TNFα-induced MUC4 expression as a novel trastuzumab resistance mechanism. We propose MUC4 expression as a predictive biomarker of trastuzumab efficacy and a guide to combination therapy of TNFα-blocking antibodies with trastuzumab. Clin Cancer Res; 23(3); 636–48. ©2016 AACR.
- Published
- 2023
17. Revised Supplementary Data from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- Author
-
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, and María F. Mercogliano
- Abstract
Revised Supplementary Data
- Published
- 2023
18. Supplementary Figure 3 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- Author
-
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, and María F. Mercogliano
- Abstract
Supplementary Figure S3. MUC4 expression and outcome of patients with luminal breast cancer respect. Kaplan-Meier analysis of the probability of DFS of patients with luminal breast cancer (HER2-negative, estrogen receptor-positive), based on the expression of MUC4. The clinicopathological characteristics of this cohort are shown in Supplementary Table S1.
- Published
- 2023
19. Supplementary Data from Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer
- Author
-
Anirban Maitra, Gregory J. Riggins, Alfonso Diaz, Fernando Pimentel, Luis Ibañez, Ivan Roa, Michael Mullendore, Seung-Mo Hong, Georg Feldmann, Robert Beaty, Jennifer Edwards, Francisco Murillo, Pedram Argani, Juan C. Roa, Alejandro Corvalan, and Hector Alvarez
- Abstract
Supplementary Data from Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer
- Published
- 2023
20. Publisher Correction: Gallbladder cancer
- Author
-
Juan C. Roa, Patricia García, Vinay K. Kapoor, Shishir K. Maithel, Milind Javle, and Jill Koshiol
- Subjects
General Medicine - Published
- 2022
21. Gallbladder cancer
- Author
-
Juan C, Roa, Patricia, García, Vinay K, Kapoor, Shishir K, Maithel, Milind, Javle, and Jill, Koshiol
- Subjects
Inflammation ,Humans ,Gallbladder Neoplasms ,Cholecystectomy ,Gallstones ,Prognosis - Abstract
Gallbladder cancer (GBC) is the most common cancer of the biliary tract, characterized by a very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour and limited therapeutic options. Early detection at a curable stage remains challenging because patients rarely exhibit symptoms; indeed, most GBCs are discovered incidentally following cholecystectomy for symptomatic gallbladder stones. Long-standing chronic inflammation is an important driver of GBC, regardless of the lithiasic or non-lithiasic origin. Advances in omics technologies have provided a deeper understanding of GBC pathogenesis, uncovering mechanisms associated with inflammation-driven tumour initiation and progression. Surgical resection is the only treatment with curative intent for GBC but very few cases are suitable for resection and most adjuvant therapy has a very low response rate. Several unmet clinical needs require to be addressed to improve GBC management, including discovery and validation of reliable biomarkers for screening, therapy selection and prognosis. Standardization of preneoplastic and neoplastic lesion nomenclature, as well as surgical specimen processing and sampling, now provides reproducible and comparable research data that provide a basis for identifying and implementing early detection strategies and improving drug discovery. Advances in the understanding of next-generation sequencing, multidisciplinary care for GBC, neoadjuvant and adjuvant strategies, and novel systemic therapies including chemotherapy and immunotherapies are gradually changing the treatment paradigm and prognosis of this recalcitrant cancer.
- Published
- 2022
22. ODP571 Blockade of ErbB-2 Nuclear Function Induces the Interferon Signaling Pathway in Breast Cancer Models Resistant to Trastuzumab
- Author
-
Patricia V Elizalde, Rosalia Cordo Russo, Santiago Madera, Sharon S Merin, María F Chervo, Esmaeil Ebrahimie, Luke Selth, Violeta A Chiauzzi, Agustina Dupont, Sabrina Barchuk, Silvina Figurelli, Daniel Lopez Della Vecchia, Pablo Guzmán, Juan C Roa, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Cecilia J Proietti, Roxana Schillaci, Theresa E Hickey, and Wayne D Tilley
- Subjects
Endocrinology, Diabetes and Metabolism - Abstract
ErbB-2, a member of ErbB family of receptor tyrosine kinases, is a key oncogenic driver in breast cancer. Despite clinical efficiency of ErbB-2-targeted therapies (trastuzumab, TZ), resistance to drugs is a major issue in the clinic. While ErbB-2 is mainly a plasma membrane-bound receptor, it also migrates to the nucleus (NErbB-2) where it can act as a transcription factor or coactivator. We previously reported that NErbB-2 is a major proliferation driver in TZ-resistant breast cancer. To investigate the NErbB-2 dependent transcriptome, RNAseq was performed using a TZ-resistant breast cancer model (JIMT-1 cells) with high constitutive levels of NErbB-2. JIMT-1 cells were transfected with an ErbB-2 nuclear localization domain mutant (hErbB-2ΔNLS), which also acts as a dominant-negative inhibitor of endogenous NErbB-2 migration. Exclusion of ErbB-2 from the nucleus resulted in up-regulation of 280 genes and down-regulation of 33 genes. Functional analysis revealed that NErbB-2 blockade enriched the expression of genes involved in type-I interferon (IFN) signaling pathway. IFNB1 and its downstream effectors OAS2 and TRIM22 were among the top up-regulated genes. In an independent breast cancer model (i. e., HCC-1569 cells), exclusion of NErbB-2 from the nucleus also induced expression of these genes. Blockade of NErbB-2 localization by injection of the hErbB-2ΔNLS mutant into JIMT-1 tumor xenografts significantly inhibited in vivo tumor growth and induced mRNA expression of IFNB1, OAS2 and TRIM22. Interestingly, blockade of NErbB-2 localization by treatment with Retro-2, an inhibitor of the retrograde transport, showed similar effects consistent with modulation of the IFN signaling pathway by NErbB-2. Bioinformatic analyses showed that both the promoter and the coding region of the IFNB1 gene contain ErbB-2 associated sequences (HAS sites). ChIP-PCR analyses revealed ErbB-2 recruitment to the HAS sites of the IFNB1 promoter and coding regions in normal growth conditions. Transfection of JIMT-1 cells with the hErbB-2ΔNLS mutant abolished the recruitment of ErbB-2 at the IFNB1 gene and also caused an increase in histone H4 acetylation, a marker of active gene transcription. NErbB-2 immunostaining in a cohort of 32 primary invasive ErbB-2-positive breast carcinomas treated with TZ revealed that NErbB-2 expression correlated with a poor disease-free survival. While this cohort is small, the findings suggest that NErbB-2 could be used as a biomarker of poor response to TZ in the clinic. In summary, our findings indicate that NErbB-2 drives the growth of TZ-resistant breast cancer cells via transcriptional repression of the IFNB1 signaling pathway, and highlight NErbB-2 as a therapeutic target and biomarker in TZ-resistant breast cancer. Presentation: No date and time listed
- Published
- 2022
23. Patients awaiting surgery for neurosurgical diseases during the first wave of the COVID-19 pandemic in Spain: a multicentre cohort study
- Author
-
Ana M Castaño-Leon, Igor Paredes, Alfonso Lagares, Pedro A Gomez, Pedro González-Leon, Angel Perez-Nuñez, Luis Jiménez-Roldán, Juan Delgado-Fernández, Carla Eiriz Fernández, Daniel García-Pérez, Luis M Moreno-Gómez, Olga Esteban-Sinovas, Pedro D Delgado-López, Javier Martín-Alonso, Ariel Kaen, Jorge Tirado-Caballero, Marta Ordóñez-Carmona, Francisco Arteaga-Romero, Marta González-Pombo, José F Alén, Ricardo Gil-Simoes, Cristina V Torres, Marta Navas-García, Guillermo Blasco García de Andoain, Natalia Frade-Porto, Patricia González-Tarno, Adrian Martin Segura, Miguel Gelabert-González, Beatriz Menéndez-Cortezón, Brais Rodríguez-Botana, Rebeca Pérez-Alfayate, Carla Fernández-García, Borja Ferrández-Pujante, Andres C Vargas-Jiménez, Carlos Cotúa, Adolfo de la Lama, Lourdes Calero Félix, Fernando Ruiz-Juretschke, Roberto García-Leal, Marc Valera-Melé, Vicente Casitas Hernando, Belén Rivero, Javier Orduna-Martínez, Juan Casado Pellejero, David Fustero De Miguel, Jorge Díaz Molina, Jesús Moles Herbera, Maria J Castelló-Ruiz, Mario Gomar-Alba, Fernando García-Pérez, Borja J Hernández-García, Jorge J Villaseñor-Ledezma, Álvaro Otero-Rodríguez, Juan J Ailagas de las Heras, Jesus Gonçalves-Estella, Pablo Sousa-Casasnovas, Daniel Pascual-Argente, Laura Ruiz Martín, Juan C Roa Montes de Oca, Daniel Arandia Guzmán, Andoni García Martín, Luis Torres Carretero, Alejandra Garrido Ruiz, Marta Calvo, Pablo Miranda-Lloret, Miguel Rodríguez-Cadarso, Joan Antón, Amparo Roca Barber, Arnold Quiroz-Tejada, Guillermo Carbayo-Lozano, Garazi Bermúdez, Clara Paternain Martin, Pablo De la Fuente Villa, Marina Fidalgo De la Rosa, Íñigo L Sistiaga-Gracia, and Gorka Zabalo
- Subjects
Paediatric neurosurgery ,SARS-CoV-2 ,Spain ,Neurosurgery ,COVID-19 ,Humans ,General Medicine ,PUBLIC HEALTH ,Adult surgery ,Pandemics ,Neurosurgical Procedures ,Retrospective Studies - Abstract
ObjectivesThe large number of infected patients requiring mechanical ventilation has led to the postponement of scheduled neurosurgical procedures during the first wave of the COVID-19 pandemic. The aims of this study were to investigate the factors that influence the decision to postpone scheduled neurosurgical procedures and to evaluate the effect of the restriction in scheduled surgery adopted to deal with the first outbreak of the COVID-19 pandemic in Spain on the outcome of patients awaiting surgery.DesignThis was an observational retrospective study.SettingsA tertiary-level multicentre study of neurosurgery activity between 1 March and 30 June 2020.ParticipantsA total of 680 patients awaiting any scheduled neurosurgical procedure were enrolled. 470 patients (69.1%) were awaiting surgery because of spine degenerative disease, 86 patients (12.6%) due to functional disorders, 58 patients (8.5%) due to brain or spine tumours, 25 patients (3.7%) due to cerebrospinal fluid (CSF) disorders and 17 patients (2.5%) due to cerebrovascular disease.Primary and secondary outcome measuresThe primary outcome was mortality due to any reason and any deterioration of the specific neurosurgical condition. Second, we analysed the rate of confirmed SARS-CoV-2 infection.ResultsMore than one-quarter of patients experienced clinical or radiological deterioration. The rate of worsening was higher among patients with functional (39.5%) or CSF disorders (40%). Two patients died (0.4%) during the waiting period, both because of a concurrent disease. We performed a multivariate logistic regression analysis to determine independent covariates associated with maintaining the surgical indication. We found that community SARS-CoV-2 incidence (OR=1.011, pConclusionsPatients awaiting neurosurgery experienced significant collateral damage even when they were considered for scheduled procedures.
- Published
- 2022
24. [Genotyping of human papillomavirus in women under 25 years old treated in the screening program for cervical cancer]
- Author
-
Angélica, Melo, Ana M, Vásquez, Alejandra, Andana, Marcela, Matamala, Tulio, Pino, Pablo, Guzmán, Rene, Hoffstetter, Carmen, Hi, Priscilla, Brebi, and Juan C, Roa
- Subjects
Young Adult ,Adolescent ,Genotype ,DNA, Viral ,Papillomavirus Infections ,Humans ,Mass Screening ,Uterine Cervical Neoplasms ,Female ,Chile ,Papillomaviridae ,Polymerase Chain Reaction ,Papanicolaou Test - Abstract
In Chile, cervical cancer (CC) is the second leading cause of death from malignancy in women. The main causal agent of cervical cancer is the human papillomavirus (HPV). This virus is the most common sexually transmitted infection among sexually active youth. An early onset of sexual life increases the chances of HPV infection; this may involve a possible early development of cervical intraepithelial neoplasia and CC, creating a major public health problem.To present HPV frequency in women under the age of 25, treated in the CC screening program and their follow-up after histopathological diagnosis.173 cervical samples were genotyped by polymerase chain reaction and non-radioactive reverse hybridization (line blot).The overall frequency of HPV was 84.8%. HPV16 was the most prevalent. In 12.1% of women the cervical lesion persisted or progressed. 28.9% of women had irregular follow-up; in this group, 88% were HPV(+) and 52% had no record of Pap smear in the past 3 years.The results reaffirm the usefulness of complementing the Pap and HPV detection as a primary screening tool in sexually active women. They also suggest the possibility of extending the age coverage of the national screening program.
- Published
- 2013
25. [Human papillomavirus genotyping in cervical adenocarcinoma in the Region of La Araucania-Chile]
- Author
-
Angélica, Melo, Patricia, García, Italo, Capurro, Pablo, Guzmán, Priscila, Brebi, Carmen, Ili, Jaime, López, and Juan C, Roa
- Subjects
Adult ,Genotype ,Papillomavirus Infections ,Uterine Cervical Neoplasms ,Adenocarcinoma ,Alphapapillomavirus ,Middle Aged ,Polymerase Chain Reaction ,DNA, Viral ,Humans ,Female ,Chile ,Polymorphism, Restriction Fragment Length ,Aged ,Retrospective Studies - Abstract
Human papillomavirus (HPV) is the main cause of cervical cancer. Thus, HPV detection and typing becomes important in order to know the frequency of genotypes present in the region. In this paper we studied 44 biopsies of cervical adenocarcinoma. For HPV detection nested polymerase chain reaction (PCR) was used to amplify the L1 gene. For viral typing restriction enzymes (Rsa I, Dde I, Pst I) and DNA sequencing were used. Viral DNA was detected by nested L1 PCR in 100% of biopsies; 38/44 cases could be typed: 81.6% HPV16; 13.2% HPV 18; 2.6% VPH 33 and 2.6% HPV 18/33.The technique was successful in identifying the virus type in 86% of biopsies. There was a strong association ACC-HPV, especially with the viral type 16, detected in 81.6% of established cases.
- Published
- 2010
26. [Detection of bone marrow micrometastases in patients with gallbladder cancer]
- Author
-
Juan C, Roa, Xabier de, Aretxabala, Angélica, Melo, Gaspar, Faría, Juan C, Araya, Miguel A, Villaseca, Pablo, Guzmán, and Iván, Roa
- Subjects
Adult ,Male ,Reverse Transcriptase Polymerase Chain Reaction ,Gene Expression ,Middle Aged ,Sensitivity and Specificity ,Bone Marrow ,Case-Control Studies ,Biomarkers, Tumor ,Humans ,Female ,Gallbladder Neoplasms ,Bone Marrow Neoplasms ,Aged - Abstract
There is a very strong documented correlation between the appearance of cancer cells in blood and occurrence of metastasis in gastrointestinal cancer.To determine MUC1, CK19, CK20 and CEA mRNA expression in bone marrow of patients with gallbladder cancer and evaluate its clinical significance.Sixty eight samples were analyzed, 38 bone marrow samples of gallbladder cancer patients, 20 healthy donors, and 10 frozen samples of gallbladder cancer. Nested reverse transcriptase-polymerase chain reaction (nested RT-PCR) was used to analyze mRNA expression.All frozen tumors were positive for CEA, CK19, and MUC1 mRNA and 70% were positive for CK20. Seventeen of 20 donor samples were positive for MUC1 and only one sample from donors was positive for both CK20 and CK19 mRNA. Among the 38 blood and bone marrow samples of gallbladder cancer patients, the expression of MUC1, CK19, CK20, and CEA, mRNA was 60.5% (23/38), 31.6% (12/38), 7.9% (3/38), and 7.9% (3/38), respectively. Disregarding the MUC1 results. 37% (14/38), 13% (5/38) and 5% (2/38) were positive for one, two and three markers respectively. Not significant differences were found in survival with a follow up to 12 months.Our results indicate that the molecular detection of tumor cells in bone marrow in patients with gallbladder carcinoma is technically possible, being CEA, CK19 and CK20 gene expression the best markers. The MUC1 gene expression marker was highly unspecific and it should not been considered. The detection of bone marrow micrometastasis might be helpful in prognosis and the selection of clinical treatment but a larger series with a longer follow-up should be studied.
- Published
- 2005
27. Erratum to: Early gallbladder carcinoma has a favorable outcome but Rokitansky–Aschoff sinus involvement is an adverse prognostic factor
- Author
-
Juan C. Roa, Oscar Tapia, Carlos Manterola, Miguel Villaseca, Pablo Guzman, Juan Carlos Araya, Pelin Bagci, Burcu Saka, and Volkan Adsay
- Subjects
Cell Biology ,General Medicine ,Molecular Biology ,Pathology and Forensic Medicine - Published
- 2013
28. Hepatobiliary cancers in South America: disparity strikes
- Author
-
Jose D Debes, Andre Boonstra, Domingo Balderramo, Angelo Z Mattos, Marco Arrese, Juan C. Roa, Juan W. Valle, Jesus M. Banales, Enrique Carrera, Pablo A. Romagnoli, Jhon E. Prieto, Bettina E. Hansen, Arndt Vogel, Angela Lamarca, and Gastroenterology & Hepatology
- Subjects
Hepatology ,business.industry ,Liver Neoplasms ,Gastroenterology ,South America ,Health Services Accessibility ,03 medical and health sciences ,Biliary Tract Neoplasms ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Humans ,Medicine ,030211 gastroenterology & hepatology ,030212 general & internal medicine ,Healthcare Disparities ,business ,Early Detection of Cancer ,Demography - Full Text
- View/download PDF
29. Patients awaiting surgery for neurosurgical diseases during the first wave of the COVID-19 pandemic in Spain: a multicentre cohort study
- Author
-
Pedro A Gomez, Alfonso Lagares, Ana M Castaño-León, Angel Pérez-Nuñez, Igor Paredes, Pedro González-Leon, Juan Delgado-Fernandez, Daniel García-Pérez, Olga Esteban-Sinovas, Javier Martín-Alonso, Ariel Kaen, Jorge Tirado-Caballero, Ricardo Gil-Simoes, Cristina V Torres, Natalia Frade-Porto, Patricia González-Tarno, Adrian Martin Segura, Miguel Gelabert-Gonzalez, Rebeca Pérez-Alfayate, Carlos Cotúa, Adolfo de la Lama, Fernando Ruiz-Juretschke, Vicente Casitas Hernando, Juan Casado Pellejero, David Fustero De Miguel, Jesus Moles Herbera, Jesús Goncalves-Estella, Laura Ruiz Martín, Daniel Arandia Guzmán, Andoni García Martín, Luis Torres Carretero, Marta Calvo, Pablo Miranda-Lloret, Amparo Roca Barber, Clara Paternain Martin, Marina Fidalgo De la Rosa, Luis Jiménez-Roldán, Carla Eiriz Fernández, Luis M Moreno-Gómez, Pedro D Delgado-López, Marta Ordóñez-Carmona, Francisco Arteaga-Romero, Marta González-Pombo, José F Alén, Marta Navas-García, Guillermo Blasco García de Andoain, Beatriz Menéndez-Cortezón, Brais Rodríguez-Botana, Carla Fernández-García, Borja Ferrández-Pujante, Andres C Vargas-Jiménez, Lourdes Calero Félix, Roberto García-Leal, Marc Valera-Melé, Belén Rivero, Javier Orduna-Martínez, Jorge Díaz Molina, Maria J Castelló-Ruiz, Mario Gomar-Alba, Fernando García-Pérez, Borja J Hernández-García, Jorge J Villaseñor-Ledezma, Álvaro Otero-Rodríguez, Juan J Ailagas de las Heras, Pablo Sousa-Casasnovas, Daniel Pascual-Argente, Juan C Roa Montes de Oca, Alejandra Garrido Ruiz, Miguel Rodríguez-Cadarso, Joan Antón, Arnold Quiroz-Tejada, Guillermo Carbayo-Lozano, Garazi Bermúdez, Pablo De la Fuente Villa, Íñigo L Sistiaga-Gracia, and Gorka Zabalo
- Subjects
Medicine - Abstract
Objectives The large number of infected patients requiring mechanical ventilation has led to the postponement of scheduled neurosurgical procedures during the first wave of the COVID-19 pandemic. The aims of this study were to investigate the factors that influence the decision to postpone scheduled neurosurgical procedures and to evaluate the effect of the restriction in scheduled surgery adopted to deal with the first outbreak of the COVID-19 pandemic in Spain on the outcome of patients awaiting surgery.Design This was an observational retrospective study.Settings A tertiary-level multicentre study of neurosurgery activity between 1 March and 30 June 2020.Participants A total of 680 patients awaiting any scheduled neurosurgical procedure were enrolled. 470 patients (69.1%) were awaiting surgery because of spine degenerative disease, 86 patients (12.6%) due to functional disorders, 58 patients (8.5%) due to brain or spine tumours, 25 patients (3.7%) due to cerebrospinal fluid (CSF) disorders and 17 patients (2.5%) due to cerebrovascular disease.Primary and secondary outcome measures The primary outcome was mortality due to any reason and any deterioration of the specific neurosurgical condition. Second, we analysed the rate of confirmed SARS-CoV-2 infection.Results More than one-quarter of patients experienced clinical or radiological deterioration. The rate of worsening was higher among patients with functional (39.5%) or CSF disorders (40%). Two patients died (0.4%) during the waiting period, both because of a concurrent disease. We performed a multivariate logistic regression analysis to determine independent covariates associated with maintaining the surgical indication. We found that community SARS-CoV-2 incidence (OR=1.011, p
- Published
- 2022
- Full Text
- View/download PDF
30. RETRACTED ARTICLE: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy
- Author
-
María C Díaz Flaqué, Natalia M Galigniana, Wendy Béguelin, Rocío Vicario, Cecilia J Proietti, Rosalía Cordo Russo, Martín A Rivas, Mercedes Tkach, Pablo Guzmán, Juan C Roa, Esteban Maronna, Viviana Pineda, Sergio Muñoz, María Florencia Mercogliano, Eduardo H Charreau, Patricio Yankilevich, Roxana Schillaci, and Patricia V Elizalde
- Subjects
Progesterone Receptor ,Progestin ,T47D Cell ,BT474 Cell ,Proximity Ligation Assay ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Introduction The role of the progesterone receptor (PR) in breast cancer remains a major clinical challenge. Although PR induces mammary tumor growth, its presence in breast tumors is a marker of good prognosis. We investigated coordinated PR rapid and nonclassical transcriptional effects governing breast cancer growth and endocrine therapy resistance. Methods We used breast cancer cell lines expressing wild-type and mutant PRs, cells sensitive and resistant to endocrine therapy, a variety of molecular and cellular biology approaches, in vitro proliferation studies and preclinical models to explore PR regulation of cyclin D1 expression, tumor growth, and response to endocrine therapy. We investigated the clinical significance of activator protein 1 (AP-1) and PR interaction in a cohort of 99 PR-positive breast tumors by an immunofluorescence protocol we developed. The prognostic value of AP-1/PR nuclear colocalization in overall survival (OS) was evaluated using Kaplan-Meier method, and Cox model was used to explore said colocalization as an independent prognostic factor for OS. Results We demonstrated that at the cyclin D1 promoter and through coordinated rapid and transcriptional effects, progestin induces the assembly of a transcriptional complex among AP-1, Stat3, PR, and ErbB-2 which functions as an enhanceosome to drive breast cancer growth. Our studies in a cohort of human breast tumors identified PR and AP-1 nuclear interaction as a marker of good prognosis and better OS in patients treated with tamoxifen (Tam), an anti-estrogen receptor therapy. Rationale for this finding was provided by our demonstration that Tam inhibits rapid and genomic PR effects, rendering breast cancer cells sensitive to its antiproliferative effects. Conclusions We here provided novel insight into the paradox of PR action as well as new tools to identify the subgroup of ER+/PR + patients unlikely to respond to ER-targeted therapies.
- Published
- 2013
- Full Text
- View/download PDF
31. CMS: a web-based system for visualization and analysis of genome-wide methylation data of human cancers.
- Author
-
Fei Gu, Mark S Doderer, Yi-Wen Huang, Juan C Roa, Paul J Goodfellow, E Lynette Kizer, Tim H M Huang, and Yidong Chen
- Subjects
Medicine ,Science - Abstract
DNA methylation of promoter CpG islands is associated with gene suppression, and its unique genome-wide profiles have been linked to tumor progression. Coupled with high-throughput sequencing technologies, it can now efficiently determine genome-wide methylation profiles in cancer cells. Also, experimental and computational technologies make it possible to find the functional relationship between cancer-specific methylation patterns and their clinicopathological parameters.Cancer methylome system (CMS) is a web-based database application designed for the visualization, comparison and statistical analysis of human cancer-specific DNA methylation. Methylation intensities were obtained from MBDCap-sequencing, pre-processed and stored in the database. 191 patient samples (169 tumor and 22 normal specimen) and 41 breast cancer cell-lines are deposited in the database, comprising about 6.6 billion uniquely mapped sequence reads. This provides comprehensive and genome-wide epigenetic portraits of human breast cancer and endometrial cancer to date. Two views are proposed for users to better understand methylation structure at the genomic level or systemic methylation alteration at the gene level. In addition, a variety of annotation tracks are provided to cover genomic information. CMS includes important analytic functions for interpretation of methylation data, such as the detection of differentially methylated regions, statistical calculation of global methylation intensities, multiple gene sets of biologically significant categories, interactivity with UCSC via custom-track data. We also present examples of discoveries utilizing the framework.CMS provides visualization and analytic functions for cancer methylome datasets. A comprehensive collection of datasets, a variety of embedded analytic functions and extensive applications with biological and translational significance make this system powerful and unique in cancer methylation research. CMS is freely accessible at: http://cbbiweb.uthscsa.edu/KMethylomes/.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.